The Gentle GH Peptide
Ipamorelin (growth hormone secretagogue)
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It is considered the most selective GHS available, as it stimulates growth hormone release from the pituitary without significantly affecting cortisol, prolactin, or ACTH levels. This selectivity gives it one of the cleanest side effect profiles in the growth hormone peptide category.
Ipamorelin selectively binds to ghrelin receptors (GHS-R1a) on the pituitary gland, triggering a burst of growth hormone release. Unlike other GHS peptides, it does not significantly stimulate cortisol, ACTH, or prolactin, providing targeted GH elevation.
Selectively activates GHS-R1a (ghrelin receptors) on pituitary somatotrophs, triggering a natural GH release pulse.
Does not significantly increase cortisol, prolactin, or ACTH levels — making it the cleanest GHS in its class.
Maintains dose-dependent GH release without desensitization of the GH axis with prolonged use.
Works synergistically with GHRH analogs (like CJC-1295) for amplified GH release beyond what either achieves alone.
The most selective growth hormone secretagogue available, providing targeted GH elevation without unwanted hormone changes.
Enhances deep wave sleep when administered before bed, aligning with the body's natural nocturnal GH release cycle for better recovery.
Cleanest side effect profile among GH peptides due to selectivity for GH release without cortisol, prolactin, or ACTH elevation.
Supports lean muscle development and fat metabolism through optimized growth hormone levels, particularly when combined with CJC-1295.
Ipamorelin demonstrated selective GH release without significant changes in cortisol, ACTH, or prolactin levels across a wide dose range in human subjects.
Long-term Ipamorelin administration maintained consistent GH release without desensitization, suggesting suitability for extended therapeutic protocols.
Ipamorelin combined with CJC-1295 produced synergistic GH release in clinical settings, establishing the combination as a preferred clinical protocol for GH optimization.
Ipamorelin has the cleanest safety profile among growth hormone secretagogues. Clinical studies have shown minimal side effects even at higher doses. Its selectivity means it avoids many of the side effects associated with other GH peptides.
Research Status
Ipamorelin has been studied in multiple clinical trials and is widely prescribed in clinical practice. It has strong evidence for selective GH release and safety. It is one of the most commonly prescribed peptides by hormone optimization physicians.
Regulatory Note
Not FDA-approved. Available through compounding pharmacies with physician prescription. Widely used in clinical anti-aging medicine.